New Service: Alicanto for Antibody Discovery from Human Serum
We recently had the pleasure of attending the PEGS Boston Conference. We had the privilege of showcasing our work through a poster presentation, a talk, and an exhibit booth. Among the highlights were engaging with experts, exchanging ideas, and strengthening our network within the community. But perhaps the most important was launching our newest service: Alicanto For Antibody Discovery From Human Serum. It was truly a great time for Abterra Biosciences!
Watch our CEO, Dr. Natalie Castellana’s presentation on Discovering SARS-CoV2 Antibodies From Patient Serum With Alicanto below. This was our first antibody discovery project utilizing human serum!
Click below to watch the presentation.
Related Posts
Rabbit Polyclonal Antibody Sequencing for Neurodegenerative Disease Research
Rabbit polyclonal antibodies are commonly used reagents across biotech and academia. As of 2024, 43% of commercial catalog antibodies are polyclonals, and 66% of those are rabbit derived. Hyperimmunized rabbits consistently generate high affinity, target-specific...
De Novo Antibody Sequencing NISTmAb with Post-Translational Modification Detection
Protein sequencing has been possible for 75 years with Edman degradation, but over the past decade, mass spectrometry (MS)-based sequencing has become the dominant approach for antibodies. The general strategy is to digest antibody proteins into short peptides using...
Monoclonal versus Polyclonal Antibody Sequencing
Antibody reagents used in biomedical research and diagnostics assays fall into two large categories: monoclonals and polyclonals. For high-quality reagents, an antibody needs to demonstrate specific reactivity in its intended assay, and maintain consistency across...
Get In Touch